Dasatinib + Quercetin (D+Q)

The protocol is administered intermittently — 100 mg of Dasatinib + 1000 mg of Quercetin for 2 consecutive days, repeated every 2-4 weeks — following the 'hit-and-run' principle: senescent cells that survive the attack take weeks to regenerate, so chronic dosing is neither necessary nor recommended.

The first human clinical trial (Hickson 2019, EBioMedicine) in patients with diabetic kidney disease showed significant reduction in senescent cells in adipose tissue and skin after 3 days of treatment. A second trial in idiopathic pulmonary fibrosis (Justice 2019) showed significant functional improvement. Multiple trials are underway for osteoarthritis, Alzheimer's, frailty, and ovarian dysfunction.

Documented side effects are mild: transient fatigue 24-48 h post-dose, slight diarrhoea, and, rarely, fluid retention. Contraindications: anticoagulants (Dasatinib increases bleeding), active cancer in treatment, pregnancy, breastfeeding, and transplanted patients.

It is the only senolytic protocol with available human clinical data but still considered experimental outside formal clinical trial contexts. In Spain it requires specialised medical prescription under compassionate use.